20200210233147urgent_medical_device_2c_inc___discussion_draft___excellence_in_audit_education___january_3_20183
There is a file included in the module called Urgent Medical Devices. This includes a case. You are going to complete part of the case requirements for this assignment. At the end of the assignment, you need to complete Steps 1 (all parts) and 3 (part A only). We will likely complete other parts later in the semester. I have to get some technology set up for you to complete the other steps. Steps 1 and 3 are about Risk Assessment. In this step you will simply identify the risks. We will consider the data files underlying those risks later. Part of the file includes some tableau visualizations that KPMG experts created. You need to look at these visualizations carefully to answer part 3.
UrgentMedical Device, Inc.: A Teaching Case Designed to Integrate Data and Analytics in
the Financial Statement Auditing Classroom
By
Allen Blay – Florida State University
Jay C. Thibodeau – Bentley University
Background
Urgent Medical Device, Inc. (the Company) is a medical device company founded in 2013 in
Provo, UT that specializes in the development and manufacturing of cutting edge medical devices
designed for all types of joint replacement surgeries. In January 2015 the FDA approved Urgent’s
premier product, a hinged titanium axle designed to provide physicians with more precise
placement of joints during joint replacement surgery.
In early 2016, approximately one year after the new product’s approval, the Company hired a new
Senior VP (SVP) of Sales to oversee sales, physician training, product delivery, and customer
service. The broad set of responsibilities allowed the charismatic SVP to significantly influence
the Company’s revenue generation. The hiring of the new SVP was also done in large part to help
guide the company’s development of an important new sales channel: third-party distributors that
are each strategically located in close proximity to key hospitals in regions around the country.
The move to hire the SVP was in direct response to overwhelming disappointment about the first
year’s sales volume for the new surgical implant, which was lagging significantly behind
expectations. Reports from the field had led management to recommend the new sales channel to
the Board of Directors which overwhelmingly approved the new strategy, the execution of which
was being led by the new SVP.
Execution of Strategy
To help execute the new strategy, the SVP hired five regional sales managers who would become
his trusted cohorts. Together, they set aggressive sales targets for the Company’s surgical implants.
The sales targets focused on achieving a growth pattern which was characterized by a record high
sales volume for each successive quarter in each region. In fact, it is fair to say that the sales
targets were intentionally created at almost unreachable levels to remove any questions about
possible weakness in demand for the Company’s new product.
The strategy focused on the development of a new sales channel with third-party distributors. Each
of the distributors had already established close relationships with the physicians that were actually
using the product during surgical procedures. To help pay for the launch of their new product,
along with the execution of the new strategy, the Company was also working hard to raise a
significant amount of new investment capital to fund the resulting increased operating costs. In
order to be successful in attracting the new investment capital, top management made it clear to
the SVP how important it was to report strong sales for its premier product, the surgical implant
for titanium joints. The SVP, in turn, passed along the same message to the regional sales
managers.
Management control philosophy
The upper management team of Urgent can be described as being aggressive in business practices
and often emphasizes speed and efficiency when implementing their decisions. Management rarely
hires external consultants because they are of the opinion that consultants are too expensive and
often follow a conservative approach. The upper management team meets regularly with its key
managers. In general, the upper management team has cooperated with the audit team in order to
provide fair and adequate financial reporting, but there have been disagreements in the past. The
Company has a strict policy for following all established internal control procedures.
Incentive Compensation
Top management focuses significant attention on achieving short-term performance measures
based on the audited financial statements when determining compensation and making promotion
decisions. Revenue earned is the most important criterion in performance assessment throughout
the organization. As part of the launch of its new surgical implant, a new bonus plan was
established to provide additional incentives for the entire organization to focus on this new
opportunity, with revenue earned as the key criterion used to determine incentive compensation.
Preliminary Results
Despite the SVP’s optimism about sales in 2017, internal reports have indicated that the actual
sales volume of the surgical implant was well below budget each quarter. The SVP responded to
these reports by repeatedly communicating his disappointment to the regional sales managers.
Furthermore, he consistently warned that if the team could not boost sales, the Company would
likely not be able to raise additional investment capital and would then be forced to significantly
downsize its headcount.
Unfortunately, boosting revenue of the new surgical implants was not as simple as merely shipping
the product to distributors. The distributors were hesitant to purchase product until the sale to the
final customer was finalized as the distributors did not want to be stuck with the inventory on their
own balance sheets. Further, the terms of the sales do not include any refund or rebate conditions.
In addition, the Company has no intention of changing those terms and accepting any returns.
Therefore, any sales to distributors are final.
By the end of 2017, the Company had signed on a total of 73 distributors to sell its surgical implants
in more than 20 different states throughout the U.S. Each distributor was independently owned
and operated but the company routinely shared best practices among its network. The SVP
monitored sales closely from the distributor network through his regional sales managers. In fact,
he even maintained a monthly sales report from each of the 73 distributors.
The Company invoices customers when the goods are shipped, and invoicing triggers the recording
of revenues. The Company does not include freight costs in sales revenue, but does offset shipping
costs with any freight charged to customers.
The following relevant financial data is taken from the Company’s unaudited trial balance, which
as used to produce the unaudited financial statements:
Sales Revenue, Year ended 12/31/2017 $84,867,855
Gross Accounts Receivable, 12/31/2017 $11,988,886
Audit Approach
Your audit team is currently in the midst of year-end testing in the revenue and accounts receivable
cycle for the audit of the calendar year 2017 financial statements. Your testing will focus on the
existence/occurrence, cut-off, and accuracy assertions for sales revenue, as well as the existence
and valuation assertions for accounts receivable. As relationships with third-party distributors
generally require significant contract analysis to ensure the appropriateness of when revenue is
recognized, the audit team expects more hours to be spent this year testing revenue and accounts
receivable as compared to the prior year. In addition to the procedures you will perform, the audit
team will also confirm accounts receivable and perform other procedures according to the audit
plan. The audit team has assessed the risk of material misstatement (RMM) for each relevant
assertion in order to determine the nature, timing, and extent of the procedures to be performed at
Urgent.
Other members of the audit team have already completed a walkthrough of the revenue and
accounts receivable processes, identified “what could go wrongs” within the process, and
identified the controls that have been placed in operation to mitigate the risks. Based on the work
performed, the team decided to test the operating effectiveness of certain key controls during
interim testing. The results are found below.
Tests of Controls – Revenue and Accounts Receivable Cycle – Interim
There are four key application controls tested at interim. Prior to testing the application controls,
the information technology (IT) auditors tested the general controls (GITCs) over program
changes, access to programs, and computer operations that are relevant to the revenue and accounts
receivable cycle. The GITCs were found to be effective and can be relied upon to support the
effective operation of application controls. In addition, the IT auditors tested the system to make
sure that proper segregation of duties occurred throughout the period and that controls over data
input, data integrity and the completion and accuracy of data used in the four application controls
were operating effectively. No exceptions were noted in the testing performed by the IT auditors
and the team decided to test the four key application controls.
The first control is an automated 3-ways sales match. The control matches the details from 1) an
approved sales order; 2) relevant shipping documents; and 3) the sales invoice before revenue is
recorded. The control has been designed to support the existence/occurrence assertion for revenue.
A test of the control’s operating effectiveness was conducted at interim. No exceptions were noted.
The second control requires the credit department at Urgent to conduct a detailed credit check for
all new customers, including the new distributors. To do so, the credit department obtains
information from the customer that allows for a comprehensive review of the financial condition
of the new customer, and an assessment of the customer’s capacity to pay outstanding invoices.
The control culminates with an approval of the new customer and the establishment of a credit
limit by the credit department manager based on the information reviewed. A test of the control’s
operating effectiveness was conducted at interim. No exceptions were noted.
The third control is an automated sales authorization control. When a sales order is entered into
the system, the amount of the sale is added to the existing accounts receivable balance for that
customer. The sum is then compared to the customer’s credit limit. If the sum is greater than the
credit limit, the sale is not approved. If the sum is less than the credit limit, the sale is approved.
A credit manager notes the approval and authorizes shipment by electronically entering their
initials into the system, which gets posted into the sales order database. A test of the control’s
operating effectiveness was conducted at interim. No exceptions were noted.
The fourth control is a monthly review of the adequacy of the allowance for doubtful accounts,
completed by the controller. On a monthly basis, the controller reviews the aging of accounts
receivable report produced by the company’s information system. During the review, the
controller identifies for follow up all balances greater than 90 days past due for consideration in
the allowance calculation. A test of the control’s operating effectiveness was conducted at interim.
No exceptions were noted.
Roll-Forward Period
By the end of the third quarter of 2017, sales revenue for the company’s premier surgical implant
was still lagging far behind expectations. To help ensure that Urgent delivered impressive fourth
quarter revenue numbers, the entire sales team, led by the SVP and the regional sales managers,
began to exert pressure on a number of distributors in an attempt to improve sales in 2017. This
effort seemed to be paying off as the sales team successfully persuaded more than a dozen
distributors to purchase product in advance of final customer demand.
These circumstances presented a problem for the Company, because the distributors began to ask
for concessions from Urgent Medical. For example, in order to persuade the distributors, the
Company agreed to hold the inventory in their own warehouse.
The SVP’s actions led to a dramatic increase in revenue for the fourth quarter of 2017. In fact,
sales increased year-over-year by 214% for the fourth quarter alone. The upward trajectory of sales
revenue helped the Company raise the much needed investment capital as Urgent issued more than
10 million shares of common stock for $40 million in early 2018.
Most importantly, roll-forward testing procedures were completed for each of the four key
application controls. No exceptions were noted in the roll-forward procedures. Thus, the audit
team concluded that the controls were operating effectively throughout the year.
Substantive Testing – Revenue and Accounts Receivable Cycle – Final
As a result of the tests of controls, the audit team assessed the control risk as low for the
existence/occurrence, cut-off and the accuracy assertions for revenue and the valuation assertion
for accounts receivable. Since the recognition of revenue is a presumed fraud risk, along with the
significant risk of sales cut-off related to the launch of the new surgical implant, the audit team
concluded that fraud risk related to the timing of revenue recognition over period end is high.
Overall, based on the control risk assessment as low and the inherent risk assessment of high, the
overall assessment of RMM is moderate for each of the assertions. In response to the RMM
assessment, the audit team has asked that you complete a number of substantive testing procedures.
In addition, since your manager is trying to improve the efficiency and effectiveness of substantive
testing, you have been asked to use two technological tools, IDEA and Tableau, to facilitate
identification of potential concerns related to the substantive testing for the revenue and accounts
receivable cycle. Urgent has provide you with the following databases to facilitate your testing.
Database Definitions for Data Provided
1) SalesOrders – Urgent has provided the SalesOrders database, which includes a master
listing of all customer orders placed during the year. The client has informed you that the
database also includes sales orders from the prior year that were not completed until the
current year, as well as orders taken this year that were not delivered to customers as of
12/31. This database is also the client’s primary database for the 3-way match control.
When an order is shipped or invoiced, the system automatically posts the ShipID or
InvoiceID to the SalesOrders database.
Column Name Column description Field type
SalesOrderID Customer order number – Primary Key
Numeric (int)
OrderDate Date the customer order was created Date
MM/DD/YYYY
ProdID Product Number. Foreign Key to
Products.ProdID
Character
CustID Distributor Number. Foreign Key to
CustomerMaster.CustID
Numeric (int)
TerritoryID Territory in which the sale was made.
Foreign key to
SalesTerritory.TerritoryID
Numeric (int)
Quantity Quantity Ordered Numeric (int)
UnitPrice Price per unit Numeric (dollars)
SubTotal Sales subtotal, amount included in Sales
Revenue
Numeric (dollars)
TaxAmt Tax amount Numeric (dollars)
Freight Shipping Cost Numeric (dollars)
TotalDue Total due from customer, amount posted
to Accounts Receivable
Numeric (dollars)
CredApr Credit Approval – Initials of CM Character
ShipID Shipping ID number – Foreign key to
Shipments.ShipID
Numeric
InvoiceID Invoice ID number – Foreign key to
Invoice.InvoiceID
Numeric
ModifiedDate Date the row was last updated Date
MM/DD/YYYY
ModifiedTime Time the row was last updated Time (24 hour)
2) Shipments – Urgent has provided you with the Shipments database, which includes a
listing of all shipments made during fiscal 2017, as well as shipments of products ordered
during 2017 and not shipped until 2018.
Column Name Column description Field type
ShipID Shipping ID Number – Primary Key Numeric (sequential int)
SalesOrderID Sales order number – Foreign key to
SalesOrders.SalesOrderID
Numeric (int)
ShipDate Date of shipment Date
MM/DD/YYYY
ShipWeight Total Weight of Shipment Numeric (int)
Carrier Shipping Carrier Character
ModifiedDate Date the row was last updated Date
MM/DD/YYYY
ModifiedTime Time the row was last updated Time (24 hour)
3) CustomerInvoices – Urgent has provided you with the CustomerInvoices database,
which includes a listing of all invoices issued during 2017, as well as invoices for sales
orders taken during 2017, but not delivered to customers until 2018.
Column Name Column description Field type
InvoiceID Invoice number – Primary Key Numeric (sequential int)
CustID Distributor ID number – Foreign key to
CustomerMaster.CustID
Numeric (int)
InvoiceDate Date of sales invoice Date
MM/DD/YYYY
SalesOrderID Sales Order ID – Foreign key to
SalesOrders
Character
PaidDate Date invoice paid, 9/9/9999 is unpaid Date
MM/DD/YYYY
ModifiedDate Date the row was last updated Date
MM/DD/YYYY
ModifiedTime Time the row was last updated Time (24 hour)
4) SalesTerritory – Urgent has provided you with this database listing the sales territories,
as well as the sales goals for the 4th quarter 2017 for all territories.
Column Name Column description Field type
TerritoryID Territory Identification Number –
Primary Key
Numeric (int)
TerritoryName Name of Sales Territory Character
SalesVP Name of Sales VP for Territory Character
SalesGoalQTR Quarterly Territory Sales Goal Numeric (dollars)
ModifiedDate Date the row was last updated Date
MM/DD/YYYY
ModifiedTime Time the row was last updated Time (24 hour)
5) CustomerMaster – Urgent has provided you with the CustomerMaster database, which
is a listing of all distributors. It classifies distributors by territory, and also includes the
most current credit limit for the customer. This credit limit is used for the automated
credit limit check control.
Column Name Column description Field type
CustID Distributor ID number – Primary Key Numeric (int)
TerritoryID Territory in which the customer is
located. Foreign key to
SalesTerritory.TerritoryID
Numeric (int)
CustName Distributor Name Character
ShipAddr Distributor Shipping Address Character
BillAddr Distributor Billing Address Character
CredLimit Credit Approval Limit Numeric (dollars)
ModifiedDate Date the row was last updated Date
MM/DD/YYYY
ModifiedTime Time the row was last updated Time (24 hour)
6) Products – Urgent provided the Products database, which includes a listing of all
products currently manufactured and sold by the company. The UnitPrice is the current
verified selling price and is automatically populated in SalesOrders when a customer
places an order. Similarly, the Weight determines the freight charged to customers.
Column Name Column description Field type
ProdID Product ID number – Primary Key Numeric (int)
ProdName Product Name Character
SafetyStockLevel Minimum inventory quantity Numeric (int)
ReManPoint Inventory level that triggers
manufacturing additional product
Numeric (int)
StandardCost Standard manufacturing cost of product Numeric (dollars)
UnitPrice Selling price Numeric (dollars)
Weight Shipping Weight of Product Decimal (8,2)
DaysToMan Number of days required to manufacture
the product
Numeric (int)
SellStartDate Date the product was available for sale Date
MM/DD/YYYY
ModifiedDate Date the row was last updated Date
MM/DD/YYYY
ModifiedTime Time the row was last updated Time (24 hour)
Your firm’s Data and Analytics center has already converted the files, as provided by the client,
into Excel format. As such, the contents and format of the databases you have been provided are
exactly the same as they were provided by the client.
Start Here Sales Summary View
3 Way Match
Dashboard
3 Way Match Test Sales by
Territory
Urgent Medical
Device Use Case
Start Here Sales Summary View 3 Way Match
Dashboard
3 Way Match Test Sales by
Territory
Q1 Q2 Q3 Q4
115.56% 81.69% 67.35%
85.33%
60.02% 74.73% 91.19%
76.05%
103.43%59.76% 82.14% 79.39%
80.08% 78.71% 61.33%
67.02%
100.96%61.52% 78.28% 63.83%
Sales by Territory |= Sales Goal ███ = Sale
s
Q1 Q2 Q3 Q4
Midwest
Northeast
Southeast
Southwest
West $5.8M$3.7M$4.5M$3.5M
$1.5M$1.4M$1.8M$1.8M
$4.1M$3.2M$3.9M$5.5M
$8.3M$6.4M$6.6M$4.8M
$4.6M$5.5M$4.5M$3.6M
Sales by Territory by Quarter
$0 $10,000,000
$20,000,000
Hinged Titanium Axle
Articular Tibial Component
Humeral Head
Acetabular Shell
Modular Femoral Head
Glenoid Component
Femoral Knee Stem
Tibial Knee Stem
Glenosphere
Tibial Baseplate
Patella Component
Metaglene
Tibial Insert
Cemented Stem
Product Sales click to filter timeline ►
Year of Invoice Date
All
Qtr of Invoice Date
All
Territory Name
Multiple values
$1.4M $8.3M
SSales
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Product Sales Timeline
Territory Name
Midwest
Northeast
Southeast
Southwest
West
Start Here Sales Summary View 3 Way Match
Dashboard
3 Way Match Test Sales by Territory
19 17 69 26 50 39 33 40 43 61 23 49
$0
$500,000
$1,000,000
$1,500,000
$2,000,000
Sa
le
s
Sales by Distributor
Southeast
Northeast
West
Midwest
Southwest
$25,977,085
$18,119,835
$17,513,945
$16,796,220
$6,460,770
Sales by Territory3 Way Match II
Midwest
Northeast
Southeast
Southwest
West
Sales Summary
View
3 Way Match
Dashboard
3 Way Match Test Sales by Territory Sales by Distributor
3-Way Match Present in Sales
Order Database
3 Way Match
Dashboard
3 Way Match Test Sales by Territory Sales by Distributor Sales by Quarter
Southeast
Northeast
West
Midwest
Southwest
$25,977,085
$18,119,835
$17,513,945
$16,796,220
$6,460,770
3 Way Match
Test
Sales by Territory Sales by Distributor Sales by Quarter
Sales by Quarter
for Each Territory
14 58 20 18 65 64 15 13 48 31 8 32 51 21 60 34 25 52 41 63 73 10 62 29
$0
$200,000
$400,000
$600,000
$800,000
$1,000,000
$1,200,000
$1,400,000
$1,600,000
$1,800,000
$2,000,000
Sa
le
s
Territory Name
Midwest
Northeast
Southeast
Southwest
West
Sales by Territory Sales by Distributor
Sales by Quarter Sales by Quarter for
Each Territory
Product Sales by
Territory
$0
$2,000,000
$4,000,000
$6,000,000
$8,000,000
$10,000,000
$12,000,000
$14,000,000
$16,000,000
$18,000,000
$20,000,000
$22,000,000
$24,000,000
Sa
le
s
$19,268,120
$24,246,390
Sales by
Distributor
Sales by Quarter Sales by Quarter for
Each Territory
Product Sales by
Territory
4th QTR Sales by
Territory
Q1 Q2 Q3 Q4
Midwest
Northeast
Southeast
Southwest
West $5.8M$3.7M$4.5M$3.5M
$1.5M$1.4M$1.8M$1.8M
$4.1M$3.2M$3.9M$5.5M
$8.3M$6.4M$6.6M$4.8M
$4.6M$5.5M$4.5M$3.6M
$1.4M $8.3M
SSales
Sales by Quarter Sales by Quarter for
Each Territory
Product Sales by
Territory
4th QTR Sales by
Territory
4th QTR Sales vs
Sales Goals
$0 $5,000,000 $10,000,000 $15,000,000 $20,000,000 $25,000,000
Hinged Titanium Axle
Articular Tibial Component
Humeral Head
Acetabular Shell
Modular Femoral Head
Glenoid Component
Femoral Knee Stem
Tibial Knee Stem
Glenosphere
Tibial Baseplate
Patella Component
Metaglene
Tibial Insert
Cemented Stem
Territory Name
Midwest
Northeast
Southeast
Southwest
West
Sales by Quarter
for Each Territory
Product Sales by
Territory
4th QTR Sales by
Territory
4th QTR Sales vs
Sales Goals
Sales by Q by
Territory vs 4th Q ..
Southeast
West
Northeast
Midwest
Southwest
$8,274,225
$5,805,140
$4,563,280
$4,095,690
$1,508,055
2M 8M
SSales
Product Sales by
Territory
4th QTR Sales by
Territory
4th QTR Sales vs
Sales Goals
Sales by Q by
Territory vs 4th Q Sa..
PCard Analysis
Video
Sales VP Territory Name
$0 $2,000,000 $4,000,000 $6,000,000 $8,000,000
Sales
Dan Kwin Southeast
Anthony Linn West
Doug Petersen Northeast
Marvin Louis Midwest
Bruce Eryans Southwest
103.43%
100.96%
76.05%
85.33%
67.02%
Sales 4th Qtr vs Budget |= Sales Goal ███ = Sales Year of Invoice Date
2017
Qtr of Invoice Date
Q4
4th QTR Sales by
Territory
4th QTR Sales vs
Sales Goals
Sales by Q by
Territory vs 4th Q Sa..
PCard Analysis Video Resources
Q1 Q2 Q3 Q4
115.56% 81.69% 67.35% 85.33%
60.02% 74.73% 91.19% 76.05%
103.43%59.76% 82.14% 79.39%
80.08% 78.71% 61.33% 67.02%
100.96%61.52% 78.28% 63.83%
Sales by Territory |= Sales Goal ███ = Sales Year of Invoice Date
2017
Qtr of Invoice Date
Multiple values
Requirements
1) According to the professional auditing standards, an audit team should ordinarily presume
that revenue recognition is a fraud risk. Complete the following steps.
a. Based on your understanding of fraud risk assessment and the case information,
identify at least three specific fraud risk factors related to Urgent. Classify these
risks in terms of What Can Go Wrong (WCGW) with each of the significant
accounts and relevant assertions identified for Urgent’s revenue and accounts
receivable cycle.
b. What do you believe is the most significant risk related to the revenue account for
Urgent?
c. What special audit considerations would you propose in response to the significant
risk you identified above? In your response, consider how you would change your
approach to the nature, timing and extent of evidence in response to the identified
risk.
2) Based on the tests of controls and other Information Technology General Controls (ITGC)
testing, your firm has concluded that the data files supplied to you for your procedures are
complete and accurate. The conclusion was based on tests of controls over data input risks
including all relevant data elements (e.g., invoice date), data integrity risks, and the relevant
automated application controls. However, it is also important to confirm that the data, once
imported into IDEA or Tableau, was transferred into the technology tool in a complete and
accurate manner prior to working with the data within the technology tool. Import all
supplied data into IDEA and then reconcile the data with the supplied trial balance and
check figures from the case. Simply stated, you must check that the data has been
transferred in a complete and accurate manner at each step in the process. Thus, to ensure
that you are working with the set of transactions and balances that the client used to
calculate Sales Revenue and Accounts Receivable, answer the following questions:
a. What are the total number of valid sales that comprise the $84,867,855 Sales
Revenue shown on the trial balance as of 12/31/2017?
b. What are the total number of unpaid invoices that comprise the $11,988,886 Gross
Accounts Receivable balance shown on the trial balance as of 12/31/2017?
3) Data visualization tools such as Tableau can be used to help audit teams identify items or
specific areas of higher risk within an entire population. Your data and analytics center
has provided you with a set of Tableau visualizations to consider during your substantive
testing procedures:
i. 3-way match of SalesOrderID, InvoiceID, and ShipID based solely on
SalesOrders database
ii. Sales by territory
iii. Sales by distributor
iv. Sales by quarter
v. Sales by territory by quarter
vi. Product sales by Territory
vii. 4th Quarter Sales by Territory
viii. Sales vs. Sales Goals for 4th quarter by Territory
ix. Sales by quarter by Territory vs 4th Q Sales Goals
a. Using the data visualizations provided in Tableau, compose a memo to be included
in the audit documentation file that identifies any patterns in the data that you
believe may be indicative of specific audit risks. In your memo, be sure to link the
identified risks to the appropriate significant account and relevant assertions.
b. Based on the analysis completed above, what further testing, if any, needs to be
performed over the identified risks and the remaining population? Stated
differently, do any further tests need to be performed or does the 3-way match
visualization, combined with your tests of controls and additional visualizations,
provide you with sufficient appropriate evidence to conclude about the occurrence
of revenue at Urgent?
4) Technology tools like IDEA can also be used to help audit teams identify items with
potentially higher risks within an entire population of items in an efficient and effective
manner. With this in mind, complete the following steps.
a. The SalesOrder database was used to produce a Tableau visualization of 3-way
match in the revenue cycle as described in the previous requirement. Using
IDEA, verify the accuracy of the SalesOrder database by creating a 3-way match
on your own using the SalesOrder, Shipments, and CustomerInvoices databases.
Are your conclusions the same? If so, how does this increase your assurance
about the accuracy of the SalesOrder database? If not, why not? Did you identify
any specific transactions that you believe should be considered higher risk for the
audit?
b. Analyze the sales revenue file using IDEA to determine whether any sales were
made to distributors without an established credit limit. Are there any exceptions?
If there are exceptions, what further testing would you perform on these
exceptions?
c. Analyze the accounts receivable and related credit authorization limits using
IDEA to determine whether any customers have account balances as of 12/31/17
that exceed their existing credit limit. Are there any exceptions to the credit limit
control as of 12/31/17? Do you notice any patterns in the exceptions? What
further testing would you perform on these exceptions?
d. For some time, Urgent has based its allowance for doubtful accounts on an aging
analysis and the results have been historically accurate. Below, you have been
provided with the client’s list of customer balances in excess of 90 days. These
are the accounts that the client will consider when calculating the allowance for
doubtful accounts as of 12/31/2017. Perform an aging analysis using IDEA to
assess the completeness and accuracy of Urgent’s list of customer balances in
excess of 90 days.
Urgent Medical Devices
Analysis of >90 Day Delinquent Accounts Receivable
As of December 31, 2017
SalesOrderID InvoiceDate TotalDue
3236 7/4/2017 56,251.34
3241 7/9/2017 73,450.67
3422 9/5/2017 73,450.67
3466 9/21/2017 59,932.09
3490 9/21/2017 54,851.15
317,935.92
i. Based on your analysis, does the client’s listing agree to your analysis
completed in IDEA?
ii. Do you have any concerns with the client’s process for identifying the
total amount of significantly delinquent accounts?
iii. According to Urgent’s unaudited trial balance, the balance for Allowance
for Doubtful Accounts is $310,000. Does the test performed above
provide sufficient appropriate evidence to support a conclusion on the
valuation of accounts receivable? If not, what additional testing would
you recommend to reach an audit conclusion for this relevant assertion?
5) Based on your risk analysis and findings in requirements 1) through 4), perform
additional analyses using IDEA to identify specific transactions, territories, or distributors
that may require additional substantive testing. Be creative when doing so. For example,
consider patterns in the data provided that might indicate management override of a
control activity. Focus your additional analytics on those areas. Prepare a listing of
specific findings from your additional analytics that you believe warrant additional
testing.
6) In order to conclude on whether the risk of material misstatement has been reduced to an
acceptably low level for the relevant assertions identified, you need to consider, on an
overall basis, whether the results of your procedures provide sufficient appropriate
evidence. Based on the evidence that you have considered, can you reach a conclusion for
the relevant assertions identified? Why or why not?
Learning Objectives of Case
1. To understand the fraud risks associated with revenue recognition and its impact
on the testing of the revenue and accounts receivable cycle (demonstrated when
students complete requirement 1 of the case).
2. To understand the importance of determining that a population of data is complete
and accurate prior to its use in audit testing, including understanding how to
reconcile the population to the underlying books and records of the audit client
(demonstrated when students complete requirement 2 of the case).
3. To learn how to interpret commonly used data visualizations and reach audit
conclusions based on the issues, objectives and alternatives that surface given the
observed facts and circumstances (demonstrated when students complete
requirement 3 of the case).
4. To understand how to utilize commonly used data and analytics software tools (i.e.,
IDEA and Tableau) within a realistic audit context (demonstrated when students
complete requirements 3, 4 and 5 of the case).
5. To develop critical thinking skills around the identification of exceptions and risk
factors in client provided data (demonstrated when students complete
requirements 3, 4 and 5 of the case).
6. Recognize the importance of reaching an overall conclusion for each relevant
assertion in accordance with applicable professional standards based on the
evidential matter considered (demonstrated when students complete
requirement 6 of the case).
- Revised Case Context – Urgent Medical Device – Case without requirements
- Urgent Medical Device, Inc – Tableau Visualizations
- Urgent Medical Device, Inc – Case Requirements